AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Zymeworks announced participation in upcoming conferences, including the ASCO Gastrointestinal Cancers Symposium and the J.P. Morgan Healthcare Conference. The company will present a Trial-in-Progress poster for ZW251, a GPC3-targeting antibody-drug conjugate for hepatocellular carcinoma, and highlight the expanding clinical profile of Ziihera across HER2-driven gastrointestinal cancers. Management will present at J.P. Morgan Healthcare Conference on January 14 at 3:00 pm Pacific Time (PT).

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet